troglitazone has been researched along with Kidney Failure, Chronic in 4 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, there was a significant reduction in insulin dosage with troglitazone treatment (22." | 2.71 | The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease. ( Arakaki, R; Bornemann, M; Genadio, V; Mohideen, P; Sugihara, J; Sugihara, V, 2005) |
| "Thus, diabetic nephropathy is currently the number one cause of end-stage renal disease in the Western world." | 2.43 | Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. ( Bakris, GL; Sarafidis, PA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, Y | 1 |
| Liu, H | 1 |
| Liu, F | 1 |
| Wang, H | 1 |
| Liu, Y | 1 |
| Duan, S | 1 |
| Mohideen, P | 1 |
| Bornemann, M | 1 |
| Sugihara, J | 1 |
| Genadio, V | 1 |
| Sugihara, V | 1 |
| Arakaki, R | 1 |
| Sarafidis, PA | 1 |
| Bakris, GL | 1 |
| Yoshida, K | 1 |
| Kohzuki, M | 1 |
| Xu, HL | 1 |
| Wu, XM | 1 |
| Kamimoto, M | 1 |
| Sato, T | 1 |
1 review available for troglitazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; E | 2006 |
1 trial available for troglitazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Hemoglobin A; Humans; Hypoglycemic Agent | 2005 |
2 other studies available for troglitazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Inhibitory effect of PPAR-gamma activator on IL-6 and mPGES protein expression in PBMC induced by homocysteine.
Topics: Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Homocysteine; Humans; Interleukin-6; In | 2005 |
Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Chromans; Humans; Hypertension; H | 2001 |